

IFW

PATENT Attorney Reference Number 4239-67287-05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.

Application No. 10/537,061

Filed: June 1, 2005

Confirmation No. 2145

For: RECOMBINANT IMMUNOTOXIN AND

USE IN TREATING TUMORS

Examiner:

Art Unit: 1653

Attorney Reference No. 4239-67287-05

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450 **CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed

May 1, 2006

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

Supplemental Information Disclosure Statement

Form 1449 and two references cited thereon

The Director is hereby authorized to charge any additional fees that may be required, or credit

over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, I

Ву

Susan Alpert Siegel, Ph.D.

Registration No. 43,121

One World Trade Center, Suite 1600 121 S.W. Salmon Street

Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.

Application No. 10/537,061

Filed: June 1, 2005

Confirmation No. 2145

For: RECOMBINANT IMMUNOTOXIN AND

USE IN TREATING TUMORS

Examiner:

Art Unit: 1653

Attorney Reference No. 4239-67287-05

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)___

Date Malled May 1, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are two English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, Deposit Authority is given on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

Susan Alpert Siegel, Ph.D.

Registration No. 43,121

cc: Docketing

MAY 0 3 2006

ATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-67287-05
Application Number	10/537,061
Filing Date	June 1, 2005
First Named Inventor	Pastan
Art Unit	1653
Examiner Name	

E		
Examiner's Initials*	ls* (optional) OTHER DOCUMENTS	
		JUHL H. et al., "Additive Cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells," <i>Immunology</i> 197:444-459 (1997) <i>Abstract only</i>
		MODAK S. et al., "Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors" <i>Cancer Research</i> 61:4048-4054 (May 2001)
	not.	
	*	

EXAMINER	DATE
SIGNATURE:	CONSIDERED:
SIGNATURE.	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.